Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Paula Rodríguez-Otero

Paula Rodríguez-Otero

University of Navarra
Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3 4:04
Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3
Paula Rodríguez-Otero • 15 Dec 2023
Investigating linvoseltamab monotherapy in SMM: the LINKER-SMM1 trial 1:56
Investigating linvoseltamab monotherapy in SMM: the LINKER-SMM1 trial
Paula Rodríguez-Otero • 15 Dec 2023
MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab 1:55
MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab
Paula Rodríguez-Otero • 15 Jun 2023
KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens 1:29
KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens
Paula Rodríguez-Otero • 15 Jun 2023
TRIMM-2 update: talquetamab + daratumumab in R/R multiple myeloma 2:49
TRIMM-2 update: talquetamab + daratumumab in R/R multiple myeloma
Paula Rodríguez-Otero • 15 Jun 2023
GEM-SELIBORDARA: selinexor plus daratumumab, bortezomib, and dexamethasone in R/R multiple myeloma 3:26
GEM-SELIBORDARA: selinexor plus daratumumab, bortezomib, and dexamethasone in R/R multiple myeloma
Paula Rodríguez-Otero • 15 Jun 2023
CAR-T therapy in myeloma: moving into earlier lines and treating patients with unmet medical needs 2:03
CAR-T therapy in myeloma: moving into earlier lines and treating patients with unmet medical needs
Paula Rodríguez-Otero • 16 Feb 2023
Session highlights: clinical indications for CAR-T therapy in multiple myeloma 2:10
Session highlights: clinical indications for CAR-T therapy in multiple myeloma
Paula Rodríguez-Otero • 16 Feb 2023
KarMMa-3 trial updates: ide-cel versus SOC in triple-class exposed R/R multiple myeloma 2:18
KarMMa-3 trial updates: ide-cel versus SOC in triple-class exposed R/R multiple myeloma
Paula Rodríguez-Otero • 16 Feb 2023
Frontline treatment of myeloma in elderly patients undergoing dialysis 2:11
Frontline treatment of myeloma in elderly patients undergoing dialysis
Paula Rodríguez-Otero • 14 May 2020
An update of COVID-19 in the hemonc clinical setting in Spain 2:28
An update of COVID-19 in the hemonc clinical setting in Spain
Paula Rodríguez-Otero • 14 May 2020
The positives of virtual hemonc meetings 0:54
The positives of virtual hemonc meetings
Paula Rodríguez-Otero • 14 May 2020
Diagnosing and treating solitary plasmacytoma 3:57
Diagnosing and treating solitary plasmacytoma
Paula Rodríguez-Otero • 17 May 2019
How to generate an anticancer immune response in multiple myeloma 3:04
How to generate an anticancer immune response in multiple myeloma
Paula Rodríguez-Otero • 29 Apr 2016
Phase I trial results for nivolumab and pembrolizumab in lymphoma and multiple myeloma 3:09
Phase I trial results for nivolumab and pembrolizumab in lymphoma and multiple myeloma
Paula Rodríguez-Otero • 29 Apr 2016
An update on immunotherapy for multiple myeloma in 2016 16:05
An update on immunotherapy for multiple myeloma in 2016
Ignacio Bermejo et al. • 16 Sep 2016
The content of VJHemOnc is intended for healthcare professionals